{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:17:29Z","timestamp":1791307049270,"version":"4.3.1"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,3,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated a randomized trial comparing the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab (R-CHOP) with CHOP alone as first-line therapy for advanced-stage MCL. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> One hundred twenty-two previously untreated patients with advanced-stage MCL were randomly assigned to six cycles of CHOP (n = 60) or R-CHOP (n = 62). Patients up to 65 years of age achieving a partial or complete remission underwent a second randomization to either myeloablative radiochemotherapy followed by autologous stem-cell transplantation or interferon alfa maintenance (IFN\u03b1). All patients older than 65 years received IFN\u03b1 maintenance. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> R-CHOP was significantly superior to CHOP in terms of overall response rate (94% v 75%; P = .0054), complete remission rate (34% v 7%; P = .00024), and time to treatment failure (TTF; median, 21 v 14 months; P = .0131). No differences were observed for progression-free survival. Toxicity was acceptable, with no major differences between the two therapeutic groups. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The combined immunochemotherapy with R-CHOP resulted in a significantly higher response rate and a prolongation of the TTF as compared with chemotherapy alone. Hence, R-CHOP may serve as a new baseline regimen for advanced stage MCL, but needs to be further improved by novel strategies in remission. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.08.133","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T01:33:13Z","timestamp":1106616793000},"page":"1984-1992","source":"Crossref","is-referenced-by-count":465,"title":["Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)"],"prefix":"10.1200","volume":"23","author":[{"given":"Georg","family":"Lenz","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Metzner","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Eimermacher","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Wandt","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalmar","family":"Steinhauer","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Martin","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"Heidemann","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aldaoud","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Parwaresch","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine III, Ludwig-Maximilians University; Department of Medical Informatics, Biometrics and Epidemiology (IBE), Ludwig-Maximilians University, Munich; Department of Internal Medicine II, St\u00e4dtisches Klinikum Braunschweig, Braunschweig; Department of Hematology, University of Essen, Essen; Department of Internal Medicine II, Klinikum Oldenburg, Oldenburg; Department of Hematology and Oncology, Katholisches Krankenhaus, Hagen, Hagen; Department of Hematology and Oncology,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Tumours of the Haemopoitic and Lymphoid Tissues . IARC Press, Lyon, France, 2001"},{"key":"R2","unstructured":"Meusers P, Hense J, Brittinger G: Mantle cell lymphoma: Diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 11:S60,1997-S64,  (suppl 2)"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"R4","unstructured":"Hiddemann W, Dreyling MH, Tiemann M, et al: Mantle cell lymphomas. Haematologica 84:93,1999-95,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4693273.x"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.057"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:10.1200\/JCO.2005.03.108","DOI":"10.1200\/JCO.2005.03.108"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059156"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702135"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701033"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200007"},{"key":"R16","unstructured":"Hiddemann W, Dreyling MH, Pfreundschuh M, et al: Myeloablative Radiochemotherapy followed by autologous Blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL): Results of a prospective randomized European Intergroup study. Blood 98:861a,2001,  (abstr 3572)"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.016"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.947"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0469"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200262"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S117"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982806"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"R28","unstructured":"World Health Organization: A handbook for reporting results of cancer treatment.  World Health Organization, Geneva, Switzerland, WHO Publication 38, 1979"},{"key":"R30","unstructured":"Hiddemann W, Dreyling MH, Forstpointner R, et al: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma: Results of a prospective randomized Trial of the German low-Grade lymphoma Study Group (GLSG). Blood 102:104,2003,  (abstr 352)"},{"key":"R31","unstructured":"Venugopal P, Wooldridge J, Yunus F, et al: Chemoimmunotherapy with combination of rituximab, GMCSF and CHOP in patients with previously untreated aggressive non Hodgkin's lymphoma. Blood 102:4930,2003,  (abstr)"},{"key":"R32","unstructured":"Romaguera J, Cabanillas F, Dang N, et al: Mantle cell lymphoma (MCL): Update on results after R-HCVAD without stem cell transplantation(SCT). Ann Oncol 13:8,2002,  (abstr)"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.864"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"R39","unstructured":"Younes A, Pro B, Delpassand E, et al: A phase II study of 90yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 102:1476,2003,  (abstr)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.08.133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:42:49Z","timestamp":1653511369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.08.133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,20]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,3,20]]}},"alternative-id":["10.1200\/JCO.2005.08.133"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.08.133","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,20]]}}}